Jeff Vacirca Buys 31,050 Shares of Caris Life Sciences (NASDAQ:CAI) Stock

Caris Life Sciences, Inc. (NASDAQ:CAI) Director Jeff Vacirca bought 31,050 shares of Caris Life Sciences stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $16.15 per share, for a total transaction of $501,457.50. Following the purchase, the director owned 49,671 shares of the company’s stock, valued at approximately $802,186.65. This trade represents a 166.75% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Caris Life Sciences Trading Down 12.4%

Shares of CAI opened at $14.69 on Thursday. The company’s fifty day moving average is $18.85. The company has a debt-to-equity ratio of 0.64, a current ratio of 7.05 and a quick ratio of 7.35. The stock has a market capitalization of $4.15 billion and a price-to-earnings ratio of -1.93. Caris Life Sciences, Inc. has a 12-month low of $14.19 and a 12-month high of $42.50.

Caris Life Sciences (NASDAQ:CAI) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.01 by $0.27. The company had revenue of $292.89 million for the quarter, compared to the consensus estimate of $281.00 million. Caris Life Sciences had a net margin of 3.75% and a return on equity of 98.28%. The firm’s revenue was up 125.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.73) EPS. Analysts predict that Caris Life Sciences, Inc. will post 0.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on CAI shares. Canaccord Genuity Group lowered their price target on Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating for the company in a report on Friday, March 13th. Piper Sandler started coverage on Caris Life Sciences in a report on Friday, April 10th. They set a “neutral” rating and a $21.00 price objective on the stock. Robert W. Baird set a $22.00 target price on Caris Life Sciences in a research report on Friday, May 8th. Weiss Ratings upgraded Caris Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Finally, The Goldman Sachs Group assumed coverage on Caris Life Sciences in a research report on Wednesday, April 1st. They set a “buy” rating and a $27.00 price target on the stock. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $27.56.

Hedge Funds Weigh In On Caris Life Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Global Retirement Partners LLC raised its stake in Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after buying an additional 999 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Caris Life Sciences by 839.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock valued at $29,000 after acquiring an additional 1,469 shares in the last quarter. Olistico Wealth LLC bought a new stake in Caris Life Sciences during the 4th quarter valued at $31,000. Fifth Third Bancorp purchased a new position in shares of Caris Life Sciences in the 1st quarter valued at $31,000. Finally, Sterling Capital Management LLC raised its position in shares of Caris Life Sciences by 128.3% in the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock worth $34,000 after acquiring an additional 1,083 shares in the last quarter.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.